Chemical modification of drug molecules as strategy to reduce interactions with mucus

被引:52
作者
Araujo, Francisca [1 ,2 ]
Martins, Claudia [1 ,2 ]
Azevedo, Claudia [1 ,2 ,3 ]
Sarmento, Bruno [1 ,2 ,4 ]
机构
[1] Univ Porto, INEB, Rua Alfredo Allen 208, P-4200393 Porto, Portugal
[2] Univ Porto, I3S, Rua Alfredo Allen 208, P-4200393 Porto, Portugal
[3] Univ Porto, ICBAS, R Jorge de Viterbo Ferreira 228, P-4150180 Porto, Portugal
[4] Inst Invest & Formacao Avancada Ciencias & Tecnol, CESPU, Rua Cent Gandra 1317, P-4585116 Gandra, Portugal
关键词
Mucus; Mucopenetration; Drug delivery; Chemical modification; Charge; Mucolytic agents; Chemical stability; Hydrophilicity; Molecular weight; ORAL INSULIN DELIVERY; HUMAN CERVICAL-MUCUS; NASAL ABSORPTION; GASTROINTESTINAL MUCUS; WEIGHT HEPARIN; HELICOBACTER-PYLORI; MUCOLYTIC AGENTS; GASTRIC MUCUS; PEPTIDE DRUGS; IN-VITRO;
D O I
10.1016/j.addr.2017.09.020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Many drug molecules possess inadequate physical-chemical characteristics that prevent to surpass the viscous mucus layer present in the surface of mucosal tissues. Due to mucus protective role and its fast turnover, these drug molecules end up being removed from the body before being absorbed and, thus, before exerting any physiologic affect. Envisaging a better pharmacokinetics profile, chemical modifications, to render drug a more mucopenetrating character, have been introduced to drug molecules backbone towards more effective therapies. Mucus penetration increases when drug molecules are provided with net-neutral charge, when they are conjugated with mucolytic agents and through modifications that makes them resistant to enzymes present in mucus. with the overall increase of their hydrophilicity and the decrease of their molecular weight. All of these characteristics act as a whole and influence each other so they must be well thought when drug molecules are being designed for mucosal delivery. (C) 2017 Published by Elsevier B.V.
引用
收藏
页码:98 / 106
页数:9
相关论文
共 114 条
[1]   Cysteine proteinase activity regulation -: A possible role of heparin and heparin-like glycosaminoglycans [J].
Almeida, PC ;
Nantes, IL ;
Rizzi, CCA ;
Júdice, WAS ;
Chagas, JR ;
Juliano, L ;
Nader, HB ;
Tersariol, ILS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (43) :30433-30438
[2]   Permeability issues in nasal drug delivery [J].
Arora, P ;
Sharma, S ;
Garg, S .
DRUG DISCOVERY TODAY, 2002, 7 (18) :967-975
[3]   The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo [J].
Atuma, C ;
Strugala, V ;
Allen, A ;
Holm, L .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2001, 280 (05) :G922-G929
[4]   MUCIN BIOPHYSICS [J].
BANSIL, R ;
STANLEY, HE ;
LAMONT, JT .
ANNUAL REVIEW OF PHYSIOLOGY, 1995, 57 :635-657
[5]   The influence of mucus microstructure and rheology in Helicobacter pylori infection [J].
Bansil, Rama ;
Celli, Jonathan P. ;
Hardcastle, Joseph M. ;
Turner, Bradley S. .
FRONTIERS IN IMMUNOLOGY, 2013, 4
[6]   CHOLERHEIC ENTEROPATHY AS A CAUSE OF DIARRHEA AND DEATH IN RADIATION-ENTERITIS AND ITS PREVENTION WITH CHOLESTYRAMINE [J].
BERK, RN ;
SEAY, DG .
RADIOLOGY, 1972, 104 (01) :153-&
[7]   Resistance to bacitracin in Bacillus subtilis:: Unexpected requirement of the BceAB ABC transporter in the control of expression of its own structural genes [J].
Bernard, Remi ;
Guiseppi, Annick ;
Chippaux, Marc ;
Foglino, Maryline ;
Denizot, Frangois .
JOURNAL OF BACTERIOLOGY, 2007, 189 (23) :8636-8642
[8]  
Bernkop-Schnfirch A., 2009, ORAL DELIVERY MACROM
[9]  
Bernkop-Schnürch A, 2007, CURR DRUG METAB, V8, P509
[10]   The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins [J].
Bernkop-Schnurch, A .
JOURNAL OF CONTROLLED RELEASE, 1998, 52 (1-2) :1-16